L Scarzella
About
In The Last Decade
L Scarzella
16 papers receiving 305 citations
Peers
Comparison fields: 5 of 56
- Neurology 211
- Cellular and Molecular Neuroscience 80
- Psychiatry and Mental health 56
- Cognitive Neuroscience 43
- Pharmacology 40
Countries citing papers authored by L Scarzella
This map shows the geographic impact of L Scarzella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Scarzella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Scarzella more than expected).
Fields of papers citing papers by L Scarzella
This network shows the impact of papers produced by L Scarzella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Scarzella. The network helps show where L Scarzella may publish in the future.
Co-authorship network of co-authors of L Scarzella
This figure shows the co-authorship network connecting the top 25 collaborators of L Scarzella. A scholar is included among the top collaborators of L Scarzella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Scarzella. L Scarzella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | Domperidone is effective in the prevention of rivastigmine-related gastrointestinal disturbances. | 4 |
| 3 | 173 | |
| 4 | Autonomic nervous function in de novo parkinsonian patients in basal condition and after acute levodopa administration. | 17 |
| 5 | Apomorphine SC treatment in parkinsonian patients with long-term L-dopa syndrome during L-dopa drug holiday. | 1 |
| 6 | Apomorphine SC treatment in parkinsonian patients with long-term L-dopa syndrome during L-dopa drug holiday. | 3 |
| 7 | Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. | 32 |
| 8 | 23 | |
| 9 | Dihydroergocryptine in the management of senile psycho-organic syndrome. | 2 |
| 10 | Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. | 38 |
| 11 | [Nicardipine in the therapy of arterial hypertension in elderly patients with the psycho-organic syndrome. Report on the results of the clinical study]. | 6 |
| 12 | [Evaluation of the effectiveness and tolerance of dihydroergotoxine and alpha methyldopa in the therapy of arterial hypertension in the elderly with senile cerebral insufficiency]. | 1 |
| 13 | 9 | |
| 14 | Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome. | 3 |
| 15 | 4 | |
| 16 | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.